Paper · 42979412
Targeting RSK2 reverses endocrine resistance in ER-positive breast cancer via inhibiting the c-Myc-ERBB4 signaling pathway.
Jiang T and 11 others. Acta Pharm Sin B, 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Targeting RSK2 reverses endocrine resistance in ER-positive breast cancer via inhibiting the c-Myc-ERBB4 signaling pathway. Papers, record 42979412. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42979412
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeting RSK2 reverses endocrine resistance in ER-positive breast cancer via inhibiting the c-Myc-ERBB4 signaling pathway.
- Journal
- Acta Pharm Sin B
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-11-05
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References45
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33,691,171 | A pan-cancer analysis of the HER family gene and their association with prognosis, tumor microenvironment, and therapeutic targets. | Life Sci | 2021 | https://conductscience.org/library/papers/33691171 | PubMed |
| 2 | 38,572,751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 3 | 20,550,710 | The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. | Mol Cancer | 2010 | https://conductscience.org/library/papers/20550710 | PubMed |
| 4 | 35,976,701 | Revisiting the multisite phosphorylation that produces the M-phase supershift of key mitotic regulators. | Mol Biol Cell | 2022 | https://conductscience.org/library/papers/35976701 | PubMed |
| 5 | 24,213,797 | Emetine enhances the tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of pancreatic cancer cells by downregulation of myeloid cell leukemia sequence-1 protein. | Oncol Rep | 2014 | https://conductscience.org/library/papers/24213797 | PubMed |
| 6 | 36,210,843 | RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36210843 | PubMed |
| 7 | 38,322,348 | Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies. | Acta Pharm Sin B | 2024 | https://conductscience.org/library/papers/38322348 | PubMed |
| 8 | 28,013,489 | RSK2 and its binding partners in cell proliferation, transformation and cancer development. | Arch Pharm Res | 2017 | https://conductscience.org/library/papers/28013489 | PubMed |
| 9 | 38,684,868 | Targeted protein degradation: from mechanisms to clinic. | Nat Rev Mol Cell Biol | 2024 | https://conductscience.org/library/papers/38684868 | PubMed |
| 10 | 32,958,832 | RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPKα2-mediated autophagy. | Oncogene | 2020 | https://conductscience.org/library/papers/32958832 | PubMed |
1 to 10 of 45
See all 45 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42979412
GET https://conductscience.org/api/papers/v1/42979412/references?page=2